Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus

J. A. Swanstrom, a J. A. Plante, a K. S. Plante, a E. F. Young, a-c E. McGowan, c E. N. Gallichotte, a-c D. G. Widman, a M. T. Heise, b,c A. M. de Silva, a R. S. Baric, c

Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; a Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; b Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

J.A.S. and J.A.P. contributed equally to this work.

ABSTRACT Zika virus (ZIKV) is a mosquito-borne flavivirus responsible for thousands of cases of severe fetal malformations and neurological disease since its introduction to Brazil in 2013. Antibodies to flaviviruses can be protective, resulting in lifelong immunity to reinfection by homologous virus. However, cross-reactive antibodies can complicate flavivirus diagnostics and promote more severe disease, as noted after serial dengue virus (DENV) infections. The endemic circulation of DENV in South America and elsewhere raises concerns that preexisting flavivirus immunity may modulate ZIKV disease and transmission potential. Here, we report on the ability of human monoclonal antibodies and immune sera derived from dengue patients to neutralize contemporary epidemic ZIKV strains. We demonstrate that a class of human monoclonal antibodies isolated from DENV patients neutralizes ZIKV in cell culture and is protective in a lethal murine model. We also tested a large panel of convalescent-phase immune sera from humans exposed to primary and repeat DENV infection. Although ZIKV is most closely related to DENV compared to other human-pathogenic flaviviruses, most DENV immune sera (73%) failed to neutralize ZIKV, while others had low (50% effective concentration [EC50], <1:100 serum dilution; 18%) or moderate to high (EC50 >1:100 serum dilution; 9%) levels of cross-neutralizing antibodies. Our results establish that ZIKV and DENV share epitopes that are targeted by neutralizing, protective human antibodies. The availability of potently neutralizing human monoclonal antibodies provides an immunotherapeutic approach to control life-threatening ZIKV infection and also points to the possibility of repurposing DENV vaccines to induce cross-protective immunity to ZIKV.

IMPORTANCE ZIKV is an emerging arbovirus that has been associated with severe neurological birth defects and fetal loss in pregnant women and Guillain-Barré syndrome in adults. Currently, there is no vaccine or therapeutic for ZIKV. The identification of a class of antibodies (envelope dimer epitope 1 [EDE1]) that potently neutralizes ZIKV in addition to all four DENV serotypes points to a potential immunotherapeutic to combat ZIKV. This is especially salient given the precedent of antibody therapy to treat pregnant women infected with other viruses associated with microcephaly, such as cytomegalovirus and rubella virus. Furthermore, the identification of a functionally conserved epitope between ZIKV and DENV raises the possibility that a vaccine may be able to elicit neutralizing antibodies against both viruses.

Zika virus (ZIKV) is an arbovirus in the Flaviviridae family, which includes important human pathogens such as Japanese encephalitis virus (JEV), West Nile virus (WNV), yellow fever virus (YFV), and dengue viruses 1 to 4 (DENV-1 to -4) (1). Flaviviruses are traditionally classified as neurovirulent (WNV and JEV) or hemorrhagic (DENV and YFV). ZIKV infection has historically been characterized by self-limiting febrile illness, including mild fever, rash, arthralgia, and conjunctivitis, and was not considered to be a pathogen of major public health concern (2, 3). However, ZIKV caused a large outbreak in Micronesia in 2007 and then throughout Polynesia and the Pacific Islands in 2013 to 2014 (4). In 2015, the first ZIKV outbreak in the Americas was reported in Brazil, where there was no previous evidence of circulation (5). Since then, 46 countries have reported novel outbreaks and ongoing transmission (4). Following the onset of the 2015 outbreak, several groups have identified an association between ZIKV infection and fetal malformations, including spontaneous abortion, intrauterine growth restriction caused by placental insufficiency, and blindness, and a causative link has been associated with microcephaly (2, 4, 6–8). The World Health Organization has also reported an increase in Guillain-Barré syndrome and meningoencephalitis associated with ZIKV (4, 9, 10). The underlying molecular mechanisms driving these severe outcomes remain largely unknown (11).
The emergence of ZIKV overlaps geographically with regions in which DENV is endemic, and ZIKV shares approximately 60% sequence identity with DENV (12). Moreover, multiple dengue vaccine candidates are in phase II and III clinical trials, including a tetravalent vaccine that is currently approved for use in regions where ZIKV is emerging (13–15). Thus, a significant portion of the population in ZIKV outbreak areas has DENV-reactive antibodies, which has complicated ZIKV diagnostics due to cross-reactivity (16). Given the extent to which DENV antibodies are present in the population, it is important to evaluate the possibility of cross-protective neutralizing epitopes that could protect against ZIKV infection. By screening a panel of monoclonal antibodies (MAbs), we found that a class of dengue virus serotype cross-neutralizing MAbs isolated from dengue patients, known as the envelope dimer epitope 1 (EDE1) MAbs, neutralize ZIKV in cell culture and protect from disease in a murine model. A few convalescent-phase immune sera from dengue patients also cross-neutralized ZIKV, further demonstrating the presence of epitopes conserved between ZIKV and DENV that are recognized by human neutralizing antibodies.

**RESULTS**

Neutralization of ZIKV by human, nonhuman primate, and mouse MAbs. To better understand antibody cross-reactivity and functionality between DENV and ZIKV, we tested a large panel of well-characterized human and mouse MAbs for binding and neutralization of two strains of ZIKV: a French Polynesian 2013 strain representing the Asiatic lineage (H/PF/2013) and a strain circulating in the Americas in 2015 (PRVABC59). As expected, human and nonhuman primate type-specific MAbs that strongly neutralize DENV-1 (1F4), DENV-2 (2D22), DENV-3 (5J7), and DENV-4 (5H2) did not neutralize ZIKV (Fig. 1A) (17–20). DENV-cross-reactive MAbs that weakly or moderately neutralized two or more DENV serotypes (4G2, 1N5, and 1M7) also failed to neutralize ZIKV (21, 22). In stark contrast, the potent DENV cross-neutralizing MAbs EDE1 C8 and EDE1 C10 strongly neutralized ZIKV (Fig. 1A) (17–20). DENV-cross-reactive MAbs that weakly or moderately neutralized two or more DENV serotypes (4G2, 1N5, and 1M7) also failed to neutralize ZIKV (21, 22). In stark contrast, the potent DENV cross-neutralizing MAbs EDE1 C8 and EDE1 C10 strongly neutralized ZIKV infection of human monocytic cells expressing DC-SIGN (23). ZIKV neutralization by EDE1 C8 and EDE1 C10 was confirmed in Vero cells (Fig. 1B). EDE1 C8 and C10 neutralization of the high-passage-number 1947 Ugandan isolate ZIKV MR766 was...
EDE1 Antibodies Neutralize Zika Virus

FIG 2 EDE1 C10 protects ZikaV-susceptible mice from infection. Five-week-old type I/II interferon receptor-knockout mice on a C57BL/6 backbone received either EDE1 C10 (n = 5) or mock (n = 5) treatment and were challenged with 10^6 FFU of ZikaV H/PF/2013. A mock cohort (n = 2) was also included. Survival (A) and weight loss (B) were monitored, and differences between the mock-treated and EDE1 C10-treated cohorts are shown.

also confirmed in Vero cells, with 50% effective concentrations (EC_{50}) of 8.9 \times 10^{-4} and 3.4 \times 10^{-4} \mu g/ml, respectively. Interestingly, EDE2 B7 (23), which strongly neutralized all four DENV serotypes, bound but did not neutralize ZikaV (Fig. 1C). Of note, the contact residues of EDE2 B7 are all part of the EDE1 epitope, except for residues 153 to 157, which were too disordered to resolve structurally when bound to DENV-2 (see Table S1 and Fig. S1 in the supplemental material) (24).

Recent studies indicate that flavivirus antibodies that neutralize virus in vitro may not necessarily be protective in vivo (25). To determine if EDE MAbs protect against ZikaV in vivo, a study was performed in type I/II interferon receptor-knockout mice, which develop ZikaV-induced morbidity and mortality (26, 27). The mice were treated with either 10 \mu g EDE1 C10 or phosphate-buffered saline (PBS) at 1 day preinfection and again at 9 days postinfection and challenged with 10^2 focus-forming units (FFU) of ZikaV H/PF/2013 or PBS in the footpad. The PBS-treated mice experienced 60% mortality following challenge (Fig. 2A), while the EDE1 C10-protected mice all survived (P < 0.05). The EDE1 C10-treated, infected mice largely exhibited no signs of illness, and their weight gain was more than that of mice that were infected with ZikaV and mock antibody but less than that of the mice that were not infected (Fig. 2B).

Neutralization of ZikaV by convalescent-phase dengue immune sera. People exposed to dengue and other flavivirus infections develop antibodies that change in magnitude and quality over time (28). The ZikaV cross-neutralizing and protective EDE1 C8 and C10 MAbs were derived from plasmablasts collected from individuals a few days after recovery from DENV infections (23). We tested whether convalescent-phase immune sera collected from DENV patients several years after primary or secondary infection contained antibodies that cross-neutralized ZikaV. We tested a panel of 17 serum samples with neutralization profiles consistent with previous exposure to primary DENV-1 (n = 5), DENV-2 (n = 4), DENV-3 (n = 5), and DENV-4 (n = 3) infections for cross-neutralization of ZikaV (see Table S2 in the supplemental material). Most of the primary sera failed to cross-neutralize ZikaV. In fact, with primary DENV immune sera, we observed lower levels of ZikaV cross-neutralization than of DENV cross-neutralization (Fig. 3; see also Fig. S2). Notable exceptions to this trend were two primary DENV-1 immune sera and one primary DENV-4 immune serum that contained moderate to high levels of ZikaV-neutralizing antibodies.

A hallmark of secondary DENV infections is the induction of dengue virus serotype cross-neutralizing antibodies which reduce the risk of disease from subsequent DENV infections (29). We tested whether convalescent-phase sera from people exposed to secondary DENV infections years previously also cross-neutralized ZikaV. All of the secondary serum samples tested neutralized DENV-1, DENV-2, and DENV-3, and 15 of 16 samples neutralized DENV-4 (Fig. 4; see also Fig. S3 in the supplemental material). There were no statistically significant differences between the DENV serotypes. In contrast, secondary DENV immune sera usually had low or undetectable levels of ZikaV cross-neutralizing antibodies. Six of the 16 sera (38%) had measurable neutralization titers against ZikaV. Five of these six individuals had modest ZikaV neutralization (EC_{50} between 1:20 and 1:100), and only one individual had strong ZikaV neutralization (EC_{50} > 1:100). Overall, secondary DENV immune sera poorly neutralized ZikaV compared to cross-neutralization phenotypes noted among other DENV serotypes, and only one individual (6%) strongly cross-neutralized ZikaV.

Antigenic cartography. The fact that convalescent-phase DENV immune human sera displayed low cross-neutralization of ZikaV suggests that ZikaV is antigenically distantly related to DENV. To examine the antigenic relationships between ZikaV and DENV, we used antigenic cartography to calculate the Euclidean distances between sera, and metric multidimensional scaling was used to render the data in three dimensions (see Movies S1 and S2 in the supplemental material). Cartography supports the hypothesis that ZikaV is antigenically more distant from DENV-1 to -4 than each DENV serotype is from the others. Moreover, ZikaV-neutralizing sera did not have universally higher DENV-neutralizing titers than ZikaV-nonneutralizing sera. Indeed, cartography suggests that neutralization titers of primary and secondary sera across all four DENV strains do not predict cross-neutralization outcomes with ZikaV, suggesting that these cross-neutralizing antibodies represent a rare subset of anti-DENV an-
DISCUSSION

Because ZIKV cocirculates with other flaviviruses, especially the four DENV serotypes, an understanding of the antigenic relationships between ZIKV and other flaviviruses and how these interactions modulate ZIKV replication, disease, and transmission is imperative. Among the pathogenic human flaviviruses, ZIKV is most closely related to DENV, and the goal of this study was to identify any shared epitopes between DENV and ZIKV targeted by cross-protective human antibodies (12). Primary DENV infections induce serotype-specific neutralizing and protective antibody responses, whereas repeat DENV infections lead to the induction of serotype cross-neutralizing and cross-protective responses (28, 30). We assessed the long-term immunological cross-reactivity of DENV sera with ZIKV using panels of MAbs and immune sera from people exposed to DENV. Neutralization assays with multiple type-specific and cross-reactive MAbs identified a single set of MAbs in our panel that could neutralize ZIKV and protect against lethal infection in vivo: EDE1 C8 and EDE1 C10. While we recognize that a broader set of human MAbs might identify novel cross-neutralizing epitopes conserved in ZIKV and DENV, the EDE1

FIG 3 Neutralization of DENV and ZIKV by DENV primary sera. Geometric mean titers of DENV-1 primary sera (A), DENV-2 primary sera (B), DENV-3 primary sera (C), and DENV-4 primary sera (D). Colored points represent individual sera, and horizontal lines represent the geometric mean titers of all sera with upper and lower 95% confidence intervals. The dotted line indicates the limit of detection for the assay. Nonneutralizing sera were assigned a value of one-half of the limit of detection for visualization and calculation of the geometric means and confidence intervals.

FIG 4 Neutralization of DENV and ZIKV by DENV secondary sera. Geometric mean titers of DENV secondary sera. Colored points represent individual sera, and horizontal lines represent the geometric mean titers of all sera with upper and lower 95% confidence intervals. The dotted line indicates the limit of detection for the assay. Nonneutralizing sera were assigned a value of one-half of the limit of detection for visualization and calculation of the geometric means and confidence intervals.
antibodies potently neutralized a French Polynesian 2013 strain representing the Asiatic lineage (H/PF/2013) and, importantly, a strain circulating in the Americas in 2015 (PRVABC59). Indeed, the dose of EDE1 C10 administered to protect in vivo (two doses of 10 μg) is far less than the 500 μg required for the fusion loop-targeting mouse MAb 2A10G6 (31). Thus, it seems likely that these EDE1 MABS will prove efficacious against multiple ZIKV strains in vivo. Consonant with this hypothesis, an alignment of the EDE1 contact residues on DENV as previously identified by X-ray crystallography and ZIKV reveals considerable conservation among contact residues between all four DENV serotypes and ZIKV, readily explaining the cross-neutralization phenotypes noted in our studies (24).

The EDE2 B7 MAb did not neutralize ZIKV despite significant epitope overlap with the EDE1 antibodies. EDE2 B7 is reported to be sensitive to the glycan at position 153 of the DENV envelope protein; ZIKV has a glycan at position 154, but the amino acid insertion in the glycan loop may alter the presentation of the glycan (23, 32). Moreover, EDE1 antibodies reach further into domains I and III, providing an additional structural framework for robust binding that may not be as strongly impacted by the insertion in the glycan loop. These data suggest that the EDE1 epitope may be critical to eliciting antibodies that protect against both DENV and ZIKV and that efforts to develop vaccines and therapeutics should emphasize this population of antibodies.

The initial description of EDE antibodies reported that they were immunodominant in nearly half of the study’s subjects (including one individual with a primary DENV infection), but there are several important caveats: the study had a small cohort (n = 7) and the frequency of EDE antibodies was not broken down into EDE1 versus EDE2 (23). Additionally, the EDE antibodies were isolated from circulating plasmablasts elicited early during the first couple of weeks following a confirmed DENV infection in Southeast Asia. It is unclear whether these EDE-expressing plasmablasts are frequently elicited across the global population, whether they are dependent on select sequential strain infection serotype patterns, and whether these plasmablasts mature into long-lived memory B cells or are lost. Nor is it known whether the level of EDE antibody expression in the circulating short- and long-term serological repertoire is sufficiently robust to protect from repeat infections. For example, while highly cross-neutralizing monoclonal antibodies can be elicited against the GII.4 human epidemic noroviruses, only a few percent of the human population actually produces these potent antibodies (33). Clearly, new diagnostic metrics such as epitope swap viruses, antibody depletion assays, and blockade of binding assays are needed to evaluate the levels of EDE antibodies in polyclonal sera after primary and secondary infection (34–37).

Some, but not all, DENV primary and secondary immune sera are capable of cross-neutralizing ZIKV. The limited cross-neutralization of ZIKV by DENV primary sera is likely attributed to the mostly type-specific long-term response that follows a single DENV infection (28). After secondary infection, DENV-elicited antibody responses are thought to maintain the type-specific response while simultaneously generating more broadly neutralizing antibodies that typically protect from further DENV infection with any serotype (30). Surprisingly, we observed no cross-neutralization of ZIKV in many individuals who had broadly cross-neutralizing antibodies to three or more DENV serotypes. We conclude that, despite the close phylogenetic relationship of DENV and ZIKV, durable long-lived antibody immune responses that broadly cross-neutralize DENV serotypes are usually not effective against ZIKV. What we did observe were clear cases of ZIKV cross-neutralization in a minority of subjects with DENV type-specific or cross-neutralizing antibody responses. The molecular basis of why some dengue-immune individuals cross-neutralize ZIKV is currently not known. Possible explanations for cross-neutralization include previous exposure to both DENV and ZIKV or the presence of EDE1 or related antibody classes in a subset of individuals. We propose that EDE1-like antibodies are, at least in part, responsible for cross-neutralizing activity in immune sera.

Gamma globulin treatment of pregnant women infected with rubella virus is associated with a reduction in harmful outcomes in the fetus (38). Similar therapies have had mixed success in preventing cytomegalovirus-driven birth defects, and immunotherapeutic human monoclonal antibody clinical trials are still ongoing (39–41). Thus, it is reasonable to assume that human monoclonal antibody therapy may be a viable treatment option to protect the developing fetus in pregnant women infected with ZIKV. Although additional therapeutic studies during infection and pregnancy will be required, the identification of an epitope that neutralizes ZIKV in vitro and in vivo represents a significant first step toward preventing ZIKV-driven fetal malformation and loss. Furthermore, the fact that the same antibodies targeting EDE1 are able to strongly neutralize both DENV and ZIKV is highly desirable, as diagnostic tests cannot always rapidly and reliably differentiate between the two infections. The strongly cross-neutralizing phenotypes of EDE1 C8 and EDE1 C10 should reduce the likelihood that a DENV patient who has been misdiagnosed with a ZIKV infection would experience disease enhancement after treatment with an EDE1 therapeutic antibody. In some individuals, the EDE1-like antibody may also be elicited by the existing tetravalent dengue vaccines already in late-stage clinical trials or available on the market. Further testing is required to determine the frequency of this antibody in the population following both natural infection and vaccination.

MATERIALS AND METHODS

Cells and viruses. All viruses were propagated in C6/36 Aedes albopictus cells as previously described. C6/36 cells were grown in minimal essential medium (Gibco, Grand Island, NY) at 32°C. Vero-81 cells were grown in Dulbecco’s modified Eagle’s medium (Gibco, Grand Island, NY), and U937 + DC-SIGN cells were maintained in RPMI 1640 (Gibco, Grand Island, NY) at 37°C. All media were supplemented with 10% (Vero-81) or 5% (C6/36 and U937 + DC-SIGN) fetal bovine serum (HyClone, Logan, UT), 0.1 mM nonessential amino acids (Gibco, Grand Island, NY), and 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco, Grand Island, NY). U937 + DC-SIGN medium was additionally supplemented with 2 mM GlutaMAX (Gibco, Grand Island, NY), 10 mM HEPES (Cellgro, Manassas, VA), and 2-mercaptoethanol (Sigma, St. Louis, MO). All cells were incubated in the presence of 5% CO₂.

ZIKV H/PF/2013 viral stocks were obtained from Michael S. Diamond (Washington University, St. Louis, MO). ZIKV PRVABC59 viral stocks were obtained from the Centers for Disease Control and Prevention (Atlanta, GA). DENV strains used in the polyclonal neutralization panel (DENV-1 WestPac74, DENV-2 S-16803, DENV-3 CH-53489, and DENV-4 TYP-376) were obtained from natural isolates maintained in the laboratory of Aravinda M. de Silva. DENV strains used in the monoclonal antibody panel (DENV-1 WestPac74, DENV-2 S-16803, DENV-3 UNC3001, and DENV-4 SriLanka 92A) were obtained from infectious clones in the laboratory of Ralph S. Baric (34, 35).

July/August 2016 Volume 7 Issue 4 e01123-16

EDE1 Antibodies Neutralize Zika Virus
Serum and antibodies. Deidentified human DENV immune sera and plasma were collected from individuals with naturally acquired DENV infections confirmed via serology. All donations were collected in compliance with the Institutional Review Board of the University of North Carolina at Chapel Hill (protocol 08-0895). Deidentified human immune sera previously collected from the Pediatric Dengue Vaccine Initiative were also used.

Monoclonal antibodies were purified from hybridomas (1M7 and 1N5) or synthetically generated by Lake Pharma (Belmont, CA) from published sequences (1F4, 2D22, S7F, 5H2, 4G2, EDE1 C8, EDE1 C10, and EDE2 B7); the latter are available upon request.

In vitro neutralization. Human sera or monoclonal antibodies were serially diluted 3-fold and mixed with sufficient virus to cause 15% infection in U937+DC-SIGN cells. Dilution medium contained reduced (2%) fetal bovine serum and was supplemented with 2 mM CaCl2 and MgCl2. The virus-antibody mixtures were incubated for 45 min in a 96-well plate at 37°C. Following this incubation, 5 × 104 cells were added and the infection was allowed to proceed for 2 h at 37°C. The volume of medium in each well was increased to 200 μL and the cells were returned to 37°C for a total of 24 h. After 24 h, the cells were fixed in paraformaldehyde, permeabilized, blocked with normal mouse serum in permeabilization buffer, and stained with Alexa Fluor 488-conjugated (Molecular Probes, Eugene, OR) 4G2 antibody. Unbound antibody was washed off, and cells were resuspended in Hanks' buffered salt solution (Gibco, Grand Island, NY) supplemented with 2% fetal bovine serum. Assays were performed twice and in duplicate. Samples were read on a Guava easyCyte 5HT flow cytometer (Millipore) as previously described by our group (42).

Neutralization in Vero-81 cells was assessed by serially diluting the monoclonal antibodies 10-fold and mixing with approximately 150 focus-forming units of virus. Dilution medium contained reduced (2%) fetal bovine serum. The virus-antibody mixtures were incubated for 1 h in a 96-well plate at 37°C and then transferred to a monolayer of Vero-81 cells in a 96-well plate. Following a further 1-h incubation at 37°C, the monolayers were overlaid with Opti-MEM (Gibco, Grand Island, NY) containing 2% fetal bovine serum and 1% (wt/vol) carboxymethyl cellulose (Sigma, St. Louis, MO). Infected plates were incubated for 2 days at 37°C with 5% CO2, at which time they were fixed with paraformaldehyde, permeabilized, blocked with normal goat serum (Sigma, St. Louis, MO) in permeabilization buffer, stained with 4G2 primary antibody followed by secondary horseradish peroxidase (HRP)-conjugated anti-mouse IgG (KPL, Gaithersburg, MD), washed again, and developed with TrueBlue secondary horseradish peroxidase (HRP)-conjugated anti-mouse IgG (KPL, Gaithersburg, MD).

Binding assays. High-binding Microlon 600 96-well plates (VWR, Radnor, PA) were coated with 100 ng of 4G2 and 2H2 antibody in 0.1 M carbonate buffer, pH 9.6, overnight at 4°C. Unbound antibody was rinsed with wash buffer (Tris-buffered saline [TBS] plus 0.2% Tween), and wells were coated with blocking buffer (TBS plus 0.05% Tween) for 1 h at 37°C. Virus was diluted in blocking buffer at a concentration sufficient to result in approximately equal reactivity with a human cross-reactive control serum and was added to the plate for 1 h at 37°C. Unbound virus was rinsed in wash buffer, and 1 μg of each primary antibody (or the control serum) diluted in blocking buffer was added to the plate for 1 h at 37°C. Unbound primary antibody was rinsed in wash buffer, and alkaline phosphatase-conjugated goat anti-human IgG antibody (Sigma, St. Louis, MO) at 1:2,500 in blocking buffer was added to the plate for 1 h at 37°C. Unbound secondary antibody was rinsed in wash buffer, the plate was developed with SigmaFast p-nitrophenyl phosphate tablets (Sigma, St. Louis, MO), and signal was read at 405 nm.

Animal studies. Cohorts of five (virus only and virus with antibody) or two (mock) 5-week-old type 1/II interferon receptor-knockout mice (Ifnar−/− and Ifngr−/−) on a C57BL/6b background were used in a single experiment. On days −1 and 9 postinfection, mice received either PBS (mock and virus only) or 10 μg EDE1 C10 antibody (virus with antibody) in a 100-μL dose delivered intraperitoneally. On day 0, mice received either PBS (mock) or 100 PU of ZIKV H/PF/2013 (virus only and virus with antibody) in a 10-μL dose delivered subcutaneously in the hind left footpad (27). Mice were monitored daily for 14 days postinfection for weight loss and signs of illness. Mice were humanely euthanized if they became moribund and counted as deceased for that day. All work was performed in adherence to the Guide for the Care and Use of Laboratory Animals (43).

Antigenic cartography. Antigenic cartography was performed using the EC50s generated from the neutralization assays with DENV-1, -2, -3, and -4 in U937+DC-SIGN cells. The data were normalized as described in the work of Cai et al. (44). Euclidean distances between sera were calculated, and metric multidimensional scaling was used to render the data in three dimensions (45). All calculations and images were generated in R Studio, version 0.99.467 (RStudio Inc., Boston, MA). Movie files were rendered using Adobe Photoshop software (Adobe, San Jose, CA).

Statistical analysis. When analyzing neutralization assays, antibody and serum concentrations were log10 transformed. Next, the EC50s were calculated using the sigmoidal dose response (variable slope) equation of Prism 6 (GraphPad Software, La Jolla, CA). Reported values were required to have at least 5,000 recorded events per data point (in the case of the U937+DC-SIGN assay), an R-squared value of greater than 0.75, a Hill slope value of at least 0.7 for monoclonal antibodies and 0.5 for sera, and an EC50 within the range of the assay. Variation between groups was measured by one-way analysis of variance (ANOVA) with a Bonferroni post hoc test. P values of less than 0.05 were considered statistically significant.

Absorbance signals for each virus group in the binding assay were multiplied or divided such that the signal for that virus against the common control serum was set to 1. Each assay was run singly with technical duplicates. Means and standard deviations were calculated in Prism 6 (GraphPad Software, La Jolla, CA).

Survival rates in the animal experiment were analyzed using the log rank (Mantel-Cox) test in Prism 6 for Windows (GraphPad Software, La Jolla, CA). The virus-with-antibody cohort was compared to the virus-only cohort.

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at http://mbio.asm.org/lookup/suppl;doi:10.1128/mBio.01123-16/-DCSupplemental. Figure S1, TIF file, 2.8 MB. Figure S2, TIF file, 0.1 MB. Figure S3, TIF file, 0.1 MB. Movie S1, MP4 file, 0.1 MB. Movie S2, MP4 file, 0.1 MB. Table S1, DOCX file, 0.1 MB. Table S2, DOCX file, 0.1 MB.

ACKNOWLEDGMENTS

We thank Vineet D. Menachery for sharing his knowledge of immunotherapies, Alex Sette and Daniela Weiskopf for providing dengue immune sera, and John G. Haughee for his expert assistance with generating videos.

This work was funded by a supplement to R.S.B. from the NIH NIAID (U19 AI 100625), a grant and supplement to A.M.D.S. from the NIH NIAID (R01 AI 107731), and a research agreement with the Gates Foundation (IDEA grant; principal investigator, Anna Durbin). K.S.P. was funded by a training grant from the NIH NIAID (T32 AI 007151-36A1). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

J.A.S. and J.A.P. designed, performed, and analyzed the neutralization data and wrote the manuscript. K.S.P. designed, performed, and analyzed the animal experiment. E.F.Y. and E.M. performed and analyzed neutralization assays. E.N.G. designed, performed, and analyzed the binding assays. D.G.W. designed and ordered the synthetic antibodies. M.T.H., A.M.D.S., and R.S.B. contributed to study design, interpretation, and manuscript review.
FUNDING INFORMATION
This work, including the efforts of Eileen McGowan, Jesica A. Swanstrom, Ellen F. Young, Emily N. Gallichotte, Aravinda de Silva, and Ralph S. Baric, was funded by HHS | National Institutes of Health (NIH) (R01 AI 100731). This work, including the efforts of Mark T. Heise, Ralph S. Baric, and Kenneth S. Plante, was funded by HHS | National Institutes of Health (NIH) (U19 AI 100625). This work, including the efforts of Kenneth S. Plante, was funded by HHS | National Institutes of Health (NIH) (T32 AI 007151-36A1). This work, including the efforts of Jessica Plante, Eileen McGowan, Aravinda de Silva, Ralph S. Baric, Jesica A. Swanstrom, Ellen F. Young, Emily N. Gallichotte, and Doug G. Widman, was funded by Bill and Melinda Gates Foundation (Bill & Melinda Gates Foundation) (Idea Grant).

REFERENCES
1. Lazear HM, Diamond MS. 2016. Zika virus: new clinical syndromes and its emergence in the western hemisphere. J Virol 90:4864–4875. http://dx.doi.org/10.1128/JVI.02522-16.
2. Brasil P, Pereira JP, Jr, Raja Gabaglia C, Damasceno L, Wakimoto M, Ribeiro Nogueira RM, Carvalho de Sequeira P, Machado Siqueira A, Abreu de Carvalho LM, Cotrim da Cunha D, Calvet GA, Neves ES, Moreira ME, Rodrigues Baiao AE, Nasser de Carvalho PR, Janzen C, Valderramos SG, Cherry JD, Bispo de Filippis AM, Nielsen-Saines K. 2016. Zika virus infection in pregnant women in Rio de Janeiro—preliminary report. N Engl J Med http://dx.doi.org/10.1056/NEJMoa1602412.
3. Brasil P, Calvet GA, Siqueira AM, Wakimoto M, de Sequeira PC, Nobre A, Quintana Mde S, Mendonca MC, Lui P, de Souza RV, Romero C, Zogbi H, Bressan CDS, Alves LS, Lourence-de-Oliveira R, Nogueira RM, Carvalho MS, de Filippis AM, Jaenisch T. 2016. Zika virus outbreak in Rio de Janeiro, Brazil: clinical characterization, epidemiological and virological aspects. PLoS Negl Trop Dis 10:e0004636. http://dx.doi.org/10.1371/journal.pntd.0004636.
4. World Health Organization. 2016. Zika virus, microcephaly and Guillian-Barré syndrome. World Health Organization, Geneva, Switzerland.
5. Zanluca C, Melo VC, Mimosain AL, Santos GL, Santos CN, Luz K. 2015. First report of autochthonous transmission of Zika virus in Brazil. Mediat Insect Oswaldo Cruz 110:569–572. http://dx.doi.org/10.1590/0074-02760150192.
6. Cavanhael S, Lopez A, Serra S, Da Cunha A, da Costa MD, Moron A, Lederman HM. 2016. Microcephaly and Zika virus: neonatal neurodevelopmental aspects. Childs Nerv Syst 32:1057–1060. http://dx.doi.org/10.1007/s00381-016-0704-6.
7. Milakar J, Korka M, Tul N, Popovic M, Poliaj-Prijatelj M, Mrzljak P, Kolenic M, Ruzic-Ilic K, Vesnaver Vipotnik T, Fabin Vodisek V, Vizjak A, Pizem J, Petrovec M, Avsici T. 2016. Zika virus infection of a novel murine model to study Zika virus pathogenesis. Am J Trop Med Hyg 90:83–90. http://dx.doi.org/10.4269/ajtmh.16-0111.
8. Ross RA, Dickson SL, Viscidi P, Bandyopadhyay S, Feldman B, Wergin W, Bhatnagar V, Duesing K, Fricke P, Hentges D, Saksena D, Srinivasan S, Bhatt S, Kajfez M, Smith AJ, Ueckert C, Diamond MS. 2016. A mouse model of Zika virus pathogenesis. Cell Host Microbe 19:795–799. http://dx.doi.org/10.1016/j.chom.2016.11.004.
9. Sirivichayakul C, Barranco-Santana EA, Esquivil-Rivera I, Oh HM, Raanan M, Sariol CA, Shek LP, Simasathan S, Smith MK, Veide JD, Wallace D, Gordon GS, Stinchcomb DT. 2016. Safety and immunogenicity of a tetravalent dengue vaccine candidate in healthy children and adults in dengue-endemic regions: a randomized, placebo-controlled phase 2 study. J Infect Dis 213:1562–1572. http://dx.doi.org/10.1093/infdis/jiv762.
10. Vazquez-K, Durbin A, Hombach J. 2016. Status of vaccine research and development of vaccines for dengue. Vaccine 34:2934–2938 http://dx.doi.org/10.1016/j.vaccine.2015.12.073.
11. Lanciotti RS, Kosoy OL, Laven JJ, Velez JO, Lambert AJ, Johnson AJ, Stanfield SM, Duffy MR. 2008. Genetic and serologic properties of Zika virus associated with an epidemic, Yap state, Micronesia, 2007. Emerg Infect Dis 14:1232–1239. http://dx.doi.org/10.3201/eid1408.0808287.
12. Fibransah G, Tan JL, Smith SA, de Alwis AR, Ng TS, Kostyukhena VA, Ibarra KD, Wang J, Harris E, de Silva A, Crowe JE, Lok SM. 2014. A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface. EMBO Mol Med 6:358–371. http://dx.doi.org/10.1002/emmm.201303404.
13. Fibransah G, Ibarra KD, Ng TS, Smith SA, Tan JL, Lim NX, Ooi JS, Kostyukhena VA, Wang J, de Silva AM, Harris E, Crowe JE, Lok SM. 2015. Dengue virus. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers. Science 349:88–91. http://dx.doi.org/10.1126/science.aaa8651.
14. Fibransah G, Tan JL, Smith SA, de Alwis R, Ng TS, Kostyukhena VA, Jadi RS, Kukkaro P, de Silva AM, Crowe JE, Lok SM. 2015. Highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. Nat Commun 6:6341. http://dx.doi.org/10.1038/ncomms7374.
15. Cockburn JJ, Navarro Sanchez ME, Goncalvez AP, Zaitseva E, Stura EA, Kikuti CM, Duquerry S, Dussart P, Chernomordik LV, Cai LJ, Rey FA. 2012. Structural insights into the neutralization mechanism of a higher primate antibody against dengue virus. EMBO J 31:767–779. http://dx.doi.org/10.1038/embj.2011.439.
16. Henchal EA, Gentry MK, McGowan JM, Brandt WE. 1982. Dengue virus-specific and flavivirus cross-reacting determinants identified with monoclonal antibodies by indirect immunofluorescence. Am J Trop Med Hyg 31:83–86.
17. Smith SA, de Alwis AR, Kose N, Harris E, Ibarra KD, Kahle KM, Paffl JM, Xiang X, Dornaz BJ, de Silva AM, Austin SK, Sukopdul-Petty S, Diamond MS, Crowe JE. 2013. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the loop C domain of protein II of the envelope protein. mBio 4.e00873-13. http://dx.doi.org/10.1128/mBio.00873-13.
18. De Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, White LJ, Diamond MS, Baris RC, Crowe JE, de Silva AM. 2012. Identification of human neutralizing antibodies that bind to complex
epitopes on dengue virions. Proc Natl Acad Sci USA 109:7439–7444. http://dx.doi.org/10.1073/pnas.1200566109.

29. Olkowski S, Forshey BM, Morrison AC, Rocha C, Vilcarromero S, Halsey ES, Kochel TJ, Scott TW, Stoddard ST. 2013. Reduced risk of disease during postsecondary dengue virus infections. J Infect Dis 208:1026–1033. doi http://dx.doi.org/10.1093/infdis/jit273.

30. Wahala WM, Silva AM. 2011. The human antibody response to dengue virus infection. Viruses 3:2374–2395. http://dx.doi.org/10.3390/v3122374.

31. D’A, Song J, Lu X, Deng YQ, Musyoki AM, Cheng H, Zhang Y, Yuan Y, Song H, Haywood J, Xiao H, Yan J, Shi Y, Qin CF, Qi J, Gao GF. 2016. Structures of the Zika virus envelope protein and its complex with a flavivirus broadly protective antibody. Cell Host Microbe 19:696–704. http://dx.doi.org/10.1016/j.chom.2016.04.013.

32. Kostyuchenko VA, Lim EX, Zhang S, Fibransah G, Ng TS, Ooi JS, Shi J, Lok SM. 2016. Structure of the thermally stable Zika virus. Nature 533:425–428. http://dx.doi.org/10.1038/nature17994.

33. Lindesmith LC, Donaldson EF, Beltramello M, Pintus S, Corti D, Swanstrom J, Debbink K, Jones TA, Lanzavecchia A, Baric RS. 2014. Particle conformation regulates antibody access to a conserved GII.4 norovirus blockade epitope. J Virol 88:8826–8842. http://dx.doi.org/10.1128/JVI.01192-14.

34. Messer WB, Yount BL, Royal SR, de Alwis R, Widman DG, Smith SA, Crowe JE, Jr, Pfaff JM, Kahle KM, Doranz BJ, Ibarra KD, Harris E, de Silva AM, Baric RS. 2016. Functional transplant of a dengue virus serotype 3 (DENV3)-specific human monoclonal antibody epitope into DENV1. J Virol 90:5096–5097. http://dx.doi.org/10.1128/JVI.01155-16.

35. Gallichotte EN, Widman DG, Yount BL, Wahala WM, Durbin A, Whitehead S, Sario CA, Crowe JE, Jr, de Silva AM, Baric RS. 2015. A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies. mBio 6:e01461-15. http://dx.doi.org/10.1128/mBio.01461-15.

36. de Alwis R, Williams KL, Schmid MA, Lai CY, Patel B, Smith SA, Crowe JE, Wang WK, Harris E, de Silva AM. 2014. Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera. PLoS Pathog 10:e1004386. http://dx.doi.org/10.1371/journal.ppat.1004386.

37. Lindesmith LC, Donaldson EF, Lobue AD, Cannon JL, Zheng DP, Vinje J, Baric RS. 2008. Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med 5:e31. http://dx.doi.org/10.1371/journal.pmed.0050031.

38. Young MK, Cripps AW, Nimmo GR, van Driel ML. 2015. Post-exposure passive immunisation for preventing rubella and congenital rubella syndrome. Cochrane Database Syst Rev 9:CD010586. http://dx.doi.org/10.1002/14651858.CD010586.pub2.

39. Revello MG, Lazzarotto T, Guerra B, Spinillo A, Ferrazzi E, Kustermann A, Guaschino S, Vergani P, Todros T, Frusca T, Arossa A, Furione M, Rognoni V, Rizzo N, Gabrielli L, Klersy C, Gerna G, CHIP Study Group. 2014. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med 370:1316–1326. http://dx.doi.org/10.1056/NEJMoa1310214.

40. Nigro G, Adler SP, La Torre R, Best AM, Congenital Cytomegalovirus Collaborating Group. 2005. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 353:1350–1362. http://dx.doi.org/10.1056/NEJMoa043337.

41. Nigro G, Adler SP, Parruti G, Anceschi MM, Cociloe E, Pezone I, Di Renzo GC. 2012. Immunoglobulin therapy of fetal cytomegalovirus infection occurring in the first half of pregnancy—a case-control study of the outcome in children. J Infect Dis 205:215–227. http://dx.doi.org/10.1093/infdis/jir718.

42. de Alwis R, Smith SA, Ovatalmez NP, Messer WB, Huynh JP, Wahala WM, White LJ, Diamond MS, Baric RS, Crowe JE, de Silva AM. 2012. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A 109:7439–7444. http://dx.doi.org/10.1073/pnas.1200566109.

43. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.

44. Cai Z, Zhang T, Wan XF. 2010. A computational framework for influenza antigenic cartography. PLoS Comput Biol 6:e1000949. http://dx.doi.org/10.1371/journal.pcbi.1000949.

45. Lindesmith LC, Ferris MT, Mullan CW, Ferreira J, Debbink K, Swanstrom J, Richardson C, Goodwin RR, Baehner F, Mendelmen PM, Bargetze RF, Baric RS. 2015. Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial. PLoS Med 12:. http://dx.doi.org/10.1371/journal.pmed.1001807.